Vator Securities advises Fragbite Group on 22 MSEK Directed Share Issue

12 October 2023

Fragbite Group AB (publ) is a Swedish corporate group with a portfolio of established subsidiaries that develop, adapt and publish games and esports content within GAMING, ESPORTS and WEB3. Their products are developed for both traditional platforms – PC, mobile and console – and modern web3 platforms built on blockchain technology.

The purpose of the directed issue is mainly to finance the acquisition of Fall Damage and the continued operation of Fall Damage and the development of its tactical First Person Shooter (“FPS”) game ALARA Prime until launch.

Read More

Vator Securities advises Medfield Diagnostics on 33 MSEK Rights Issue

30 June 2023

Medfield is a medical technology company that has developed the product MD100 Strokefinder, a device powered by AI and microwave technology that can distinguish stroke patients from healthy individuals and differentiate between strokes caused by a clot and those caused by a hemorrhage.

By routing the patient directly to a stroke or trauma center, qualified treatment can be started much faster, leading to time savings, faster care, better outcomes, and lower healthcare costs. The company generates revenue through the sale of the MD100 system, software upgrades, service and maintenance, and disposable materials.

Read More

Vator Securities advises Moberg Pharma on 100 MSEK Rights Issue

28 June 2023

Moberg Pharma AB (publ) is a Swedish pharmaceutical company with a focus on the commercialization of proprietary medicines based on proven substances. The company’s main asset is MOB-015 – a new topical treatment for nail fungus. Phase 3 clinical studies of more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis.

Moberg Pharma has agreements with commercial partners on site in Europe and Canada, among others. MOB-015 was recommended for market approval in the EU June 2023.

Read More

Vator Securities advises ZignSec on 26 MSEK Rights Issue

12 June 2023

ZignSec is a RegTech company, providing an integrated end-to-end KYC, KYB compliance platform, facilitating seamless customer onboarding and monitoring, so clients can confidently expand operations internationally while remaining compliant.

The platform is constantly evolving by addition of best-of-breed services and tools to enhance the customer experience. ZignSec has hundreds of customers spread across a range of industries where identification is essential, with the greatest concentration in financial services and other regulated activities.

Read More

Vator Securities advises AAC Clyde Space on 74 MSEK Rights Issue

7 June 2023

AAC Clyde Space is a leading global small satellite specialist with the goal of becoming a world leader in providing high-quality and timely space data (Space Data as a Service), which can be applied to meet global challenges and improve life on Earth. To date, ~30 satellites have been designed, manufactured, and launched.

AAC Clyde Space specializes in small satellite technologies and services that enable businesses, governments, and educational organizations to access high-quality, timely data from space.

Read More

Vator Securities advises ChromoGenics on 30 MSEK Rights Issue

17 May 2023

ChromoGenics is a proptech company producing smart dynamic glass that improves indoor environments and well-being whilst lowering the buildings’ energy consumption, operating expenses and climate impact. The company’s product ConverLight® Dynamic is based on a unique patented technology from the Ångström Laboratory in Uppsala, where electrochromic coatings are sputtered onto plastic film.

The result is a dynamic film that can be laminated between glass layers, which provides buildings with exceptional solar protection and lowered environmental impact from production,transport and use. The dynamic film is easy to transport and can be applied by local partners in the glass industry, which means it is possible to avoid long-distance and polluting shipping of bulky glass.

Read More

Vator Securities acts as Sole Global Coordinator and Sole Bookrunner in ExpreS2ion Biotechnologies 102 MSEK Rights Issue

4 March 2023

ExpreS2ion Biotechnologies is a biotechnology company that develops vaccines based on complex proteins targeting infectious diseases and cancer. The company develops a pipeline of preventive and therapeutic vaccine products while generating revenue by outlicensing the company’s ExpreS2 platform.

The lead candidate targeting COVID-19 is outlicensed to Bavarian Nordic, with positive phase II data announced in February 2022 and phase III initiated during September 2022. ExpreS2ion has a strong pipeline with multiple candidates in pre-clinical phase.

Read More

Vator Securities acted as Sole Global Coordinator and Sole Bookrunner in Immunovia 202 MSEK Rights Issue

20 February 2023

Immunovia is a diagnostics company with the vision to revolutionize blood-based diagnostics and increase the survival rate for patients with cancer. Immunovia has launched the first blood test in the world designed for the early detection of pancreatic cancer, a serious form of cancer with a low survival rate. The low survival rate is explained by the fact that pancreatic cancer is usually detected at a late stage when the tumor has metastasized.

Immunovia has developed IMMray® PanCan-d, which is the first blood-based test specifically developed for the early diagnosis of pancreatic ductal adenocarcinoma (PDAC). Since 2016, Immunovia has conducted several large-scale studies targeting the main pancreatic cancer risk groups. Altogether, the studies have been conducted at around 30 hospitals in the USA and Europe and included several thousand patients. Based on the studies conducted, Immunovia’s assessment is that IMMray® PanCan-d has unmatched clinical performance for the early detection of pancreatic cancer.

Read More